Mizuho analyst Salim Syed raised the firm’s price target on BridgeBio to $60 from $50 and keeps a Buy rating on the shares. The analyst updated biotech models post the Q2 earnings reports.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BBIO:
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- BridgeBio reports inducement grants under Nasdaq listing rule
- BridgeBio Pharma Reports Second Quarter 2023 Financial Results and Business Update
- BridgeBio sees cash runway into 2H24
- BridgeBio reports Q2 EPS (98c), consensus (83c)